The number of suicides among US military members and their families slightly decreased in 2022; Democratic lawmakers proposed legislation that would require employers to provide paid time off following a pregnancy loss; Pfizer and BioNTech’s flu–COVID-19 vaccine generated a strong immune response against strains of the viruses in an early- to mid-stage trial.
The number of suicides among US military members and their families slightly decreased in 2022, according to the Associated Press. US officials clarified that although the total number of deaths decreased, suicides among active-duty troops slightly increased due to significant spikes in the Marine Corps and the Air Force. Overall, US officials explained that, due to the decreasing number of active-duty members, they believe the rate of suicides, rather than the number, is a more accurate measure. Because most military suicides are by firearm, an independent committee recommended the Department of Defense implement gun safety measures to reduce suicides in the force, but the department has so far shied away from any major changes.
Democratic lawmakers introduced legislation on Thursday that would require employers to provide paid time off following a pregnancy loss, according to Axios. The bill proposed by Sen Tammy Duckworth (D, Illinois) and Rep Ayanna Pressley (D, Massachusetts) would require employers to provide 7 days of paid leave annually for those who experience a miscarriage, a medical issue affecting pregnancy or fertility, or an unsuccessful adoption or surrogacy. The bill would also provide the National Institutes of Health with $45 million for pregnancy loss research and require the CDC to develop educational resources on the topic. Axios explained that the bill currently stands little chance in Congress due to the divide, but Duckworth said she is still pushing to get Republican cosponsors.
Pfizer and BioNTech announced Thursday that their vaccine used to prevent both the flu and COVID-19 generated a strong immune response against strains of the viruses in an early- to mid-stage trial, according to Reuters. During the trial, they compared a licensed influenza vaccine and the companies’ updated COVID-19 vaccine, both of which were given to vaccine candidates during the same visit. The companies noted that the trial data showed that the flu–COVID-19 vaccine demonstrated robust immune responses to SARS-CoV-2 strains, influenza A, and influenza B. Consequently, the companies plan to start a late-stage trial in the coming months.
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Health Equity, Accessibility Essential to Supporting Women Affected by Hemophilia
May 10th 2024Due to often being overlooked as only carriers of hemophilia, the review authors sought to highlight the needs of female caretakers for patients with the disorder and the possibility of women themselves being affected by it.
Read More